A detailed history of Gladius Capital Management LP transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Gladius Capital Management LP holds 5,500 shares of VNDA stock, worth $26,950. This represents 0.02% of its overall portfolio holdings.

Number of Shares
5,500
Previous 5,500 -0.0%
Holding current value
$26,950
Previous $25,000 -0.0%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$4.61 - $6.34 $3,840 - $5,281
-833 Reduced 13.15%
5,500 $25,000
Q2 2024

Jul 18, 2024

SELL
$3.91 - $6.5 $12,429 - $20,663
-3,179 Reduced 33.42%
6,333 $35,000
Q1 2024

May 14, 2024

BUY
$3.47 - $4.61 $8,171 - $10,856
2,355 Added 32.9%
9,512 $39,000
Q4 2023

Feb 07, 2024

BUY
$3.38 - $4.58 $7,040 - $9,540
2,083 Added 41.05%
7,157 $30,000
Q3 2023

Dec 18, 2023

BUY
$4.28 - $6.57 $487 - $748
114 Added 2.3%
5,074 $21,000
Q3 2023

Oct 10, 2023

BUY
$4.28 - $6.57 $487 - $748
114 Added 2.3%
5,074 $22,000
Q2 2023

Dec 18, 2023

SELL
$5.9 - $6.95 $672 - $792
-114 Reduced 2.25%
4,960 $32,000
Q2 2023

Aug 08, 2023

BUY
$5.9 - $6.95 $1,492 - $1,758
253 Added 5.37%
4,960 $33,000
Q1 2023

Dec 18, 2023

SELL
$6.18 - $7.99 $2,268 - $2,932
-367 Reduced 7.23%
4,707 $31,000
Q1 2023

May 09, 2023

BUY
$6.18 - $7.99 $7,595 - $9,819
1,229 Added 35.34%
4,707 $32,000
Q4 2022

Dec 18, 2023

SELL
$6.87 - $10.96 $10,964 - $17,492
-1,596 Reduced 31.45%
3,478 $25,000
Q4 2022

Feb 02, 2023

BUY
$6.87 - $10.96 $336 - $537
49 Added 1.43%
3,478 $26,000
Q3 2022

Nov 14, 2022

SELL
$9.44 - $11.76 $5,739 - $7,150
-608 Reduced 15.06%
3,429 $34,000
Q2 2022

Aug 10, 2022

BUY
$9.31 - $11.84 $37,584 - $47,798
4,037 New
4,037 $45,000

Others Institutions Holding VNDA

About Vanda Pharmaceuticals Inc.


  • Ticker VNDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,561,500
  • Market Cap $277M
  • Description
  • Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...
More about VNDA
Track This Portfolio

Track Gladius Capital Management LP Portfolio

Follow Gladius Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Gladius Capital Management LP with notifications on news.